NASDAQ:NGEN NervGen Pharma (NGEN) Stock Price, News & Analysis $1.99 -0.06 (-2.93%) Closing price 09/21/2026 04:00 PM EasternExtended Trading$2.09 +0.10 (+5.03%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC FilingsShort Interest About NervGen Pharma Stock (NASDAQ:NGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NervGen Pharma alerts:Sign Up Key Stats Today's Range$1.96▼$2.0650-Day Range$1.59▼$2.3452-Week Range$1.58▼$6.30Volume473,568 shsAverage Volume633,446 shsMarket Capitalization$160.45 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingModerate Buy Company Overview NervGen Pharma Corp. is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, focused on developing treatments that promote repair and recovery following damage to the nervous system. The company’s research is based on technology involving protein tyrosine phosphatase sigma, a receptor associated with the inhibition of nerve regeneration. NervGen’s lead product candidate is NVG-291, an investigational peptide designed to support neural repair, axonal regeneration and functional recovery. The company has been evaluating NVG-291 in clinical development for spinal cord injury and has also identified potential applications in conditions such as peripheral nerve injury and multiple sclerosis. Its programs are intended to address nervous-system damage for which existing treatment options are limited. The company’s development efforts build on research associated with scientists including Dr. Jerry Silver of Case Western Reserve University. NervGen conducts its corporate and clinical activities primarily from Canada while pursuing development opportunities and clinical research involving patients and institutions in North America. The company is led by President and Chief Executive Officer Mike Kelly.AI Generated. May Contain Errors. Read More NervGen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreNGEN MarketRank™: NervGen Pharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 493rd out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingNervGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNervGen Pharma has a consensus price target of $14.00, representing about 603.5% upside from its current price of $1.99.Amount of Analyst CoverageNervGen Pharma has only been the subject of 2 research reports in the past 90 days.Read more about NervGen Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NervGen Pharma are expected to decrease in the coming year, from ($0.46) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NervGen Pharma is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NervGen Pharma is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNervGen Pharma has a P/B Ratio of 66.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.17% of the float of NervGen Pharma has been sold short.Short Interest Ratio / Days to CoverNervGen Pharma has a short interest ratio ("days to cover") of 8.29.Change versus previous monthShort interest in NervGen Pharma has recently increased by 2.01%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNervGen Pharma does not currently pay a dividend.Dividend GrowthNervGen Pharma does not have a long track record of dividend growth. News and Social Media4.0 / 5News SentimentN/A News SentimentNervGen Pharma has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for NervGen Pharma this week, compared to 3 articles on an average week.Search Interest4 people have searched for NGEN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows7 people have added NervGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NervGen Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsNervGen Pharma has minimal institutional ownership at this time.Read more about NervGen Pharma's insider trading history. Receive NGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGEN Stock News HeadlinesNervGen to Host Inaugural R&D Day on September 30, 2026September 9, 2026 | globenewswire.comNervGen Pharma Corp.: NervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | finanznachrichten.deDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December. | Porter & Company (Ad)NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash PositionAugust 13, 2026 | tipranks.comNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | globenewswire.comNervGen Pharma Corp. : NGENJuly 13, 2026 | 247wallst.comNervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink PartnersJuly 2, 2026 | tipranks.comNervGen Pharma: I Think The Biggest Risks Are Now Behind ItJuly 2, 2026 | seekingalpha.comSee More Headlines NGEN Stock Analysis - Frequently Asked Questions How have NGEN shares performed this year? NervGen Pharma's stock was trading at $3.85 on April 27, 2026. Since then, NGEN stock has decreased by 48.3% and is now trading at $1.99. How were NervGen Pharma's earnings last quarter? NervGen Pharma (NASDAQ:NGEN) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.28. Who are NervGen Pharma's major shareholders? NervGen Pharma's top institutional investors include Empery Asset Management LP (4.96%), Stonepine Capital Management LLC (0.34%), Bank of America Corp DE (0.23%) and AXQ Capital LP (0.05%). How do I buy shares of NervGen Pharma? Shares of NGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/22/2026Status update9/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NGEN CIK1751912 Webnervgen.com Phone(604) 722-5361FaxN/AEmployees8Year Founded2017Price Target and Rating Average Price Target for NervGen Pharma$14.00 High Price Target$18.00 Low Price Target$10.00 Potential Upside/Downside+603.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,259.82% Return on Assets-199.79% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book66.33Miscellaneous Outstanding Shares80,630,000Free FloatN/AMarket Cap$160.45 million OptionableN/A BetaN/A Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:NGEN) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored10% yields… from a gold security?Most stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the wor...Golden Portfolio | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
